Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WCCS 2016 /
Targeted therapies in melanoma

31st Aug - 3rd Sep 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.09.16
Views: 1342

Dr Dirk Schadendorf - University Hospital Essen, Essen, Germany

Dr Schadendorf speaks with ecancertv at WCCS 2016 about coping with resistance to targeted therapies in melanoma.

Looking at the survival rate of melanoma with current therapies compared to recent history, Dr Schadendorf highlights a greater understanding of which mutations confer resistance to targeted pathways as a necessary step to increase treatment efficacy.

He also considers the challenges of diagnosis and treatment of rare mutational subgroups, which can exhibit unusual vulnerabilities to molecular therapy.

Lastly, Dr Schadendorf discusses the patients from Checkmate 065 and 069 who discontinued therapy after a period of severe side effects; it appears a small group among those who received checkmate regulatory therapy exhibited an overall accelerated response and recovery.

ecancer's filming at WCCS 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation